REFERENCES
1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Pugh S, Thomas GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994;355:675-8.
3. Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, et al. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;1262:425-31.
4. Singh Ranger G. Current Concepts in colorectal cancer prevention with cyclooxygenase inhibitors. Anticancer Res 2014;34:6277-82.
6. Adegboyega PA, Ololade O. Immunohistochemical expression of cyclooxygenase-2 in normal kidneys. Appl Immunohistochem Mol Morphol 2004;12:71-4.
7. Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 2004;24:2349-51.
8. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23.
9. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
10. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241-6.
11. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85:1220-4.
12. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005;294:47-55.
13. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.
14. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741-50.
15. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
16. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015;26:47-57.
17. Breuer-Katschinski B, Nemes K, Rump B, Leiendecker B, Marr A, et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion 2000;61:129-34.
18. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S-64S.
19. Patrono C, Patrignani P, Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001;108:7-13.
20. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
21. Langley RE, Rothwell PM. Potential biomarker for aspirin use in colorectal cancer therapy. Nat Rev Clin Oncol 2013;10:8-10.
22. Jung YR, Kim EJ, Choi HJ, Park JJ, Kim HS, et al. Aspirin targets SIRT1 and AMPK to induce senescence of colorectal carcinoma cells. Mol Pharmacol 2015;88:708-19.
23. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004;75:40-7.
25. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
26. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost 2003;1:1710-13.
27. Gibaldi M, Grundhofer B. Bioavailability of aspirin from commercial suppositories. J Pharm Sci 1975;64:1064-6.
28. Sagar KA, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal 1999;21:383-92.
29. Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, et al. Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers. Can J Physiol Pharmacol 1991;69:1436-42.
30. Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long term treated patients. J Am Coll Cardiol 2004;43:979-84.
31. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
32. Tran HV, Waring ME, McManus DD, Erskine N, Do VTH, et al. Underuse of Effective Cardiac Medications Among Women, Middle-Aged Adults, and Racial/Ethnic Minorities With Coronary Artery Disease (from the National Health and Nutrition Examination Survey 2005 to 2014). Am J Cardiol 2017;120:1223-9.
33. Singh Ranger G, McKinley-Brown C. Aspirin utilization, compliance and prevention of colorectal cancer - A single centre perspective. Available from: https://academic.oup.com/annonc/article/27/suppl_6/1342P/2800238. [Last accessed on 19 Nov 2018].
